source
- Sentivera secures up to $1.5 billion licensing deal for inflammatory disease candidateSentivera, a biotech startup formed by investors behind Metsera, announced a licensing agreement with Shanghai-listed Haisco Pharmaceutical. Under the deal, Sentivera will pay Haisco $40 million u…
- Haisco partners with US VCs to launch immunology biotech Sentivera with up to $1.5B fundingHaisco Pharmaceutical Group announced the creation of a new immunology-focused biotech called Sentivera, backed by two American venture‑capital firms, Population Health Partners and ARCH Venture Pa…